
|Videos|June 29, 2011
Dr. Vogelzang Discusses Cabozantinib's Dose Size
Author(s)Nicholas J. Vogelzang, MD
Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size
Advertisement
Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026
4
Unanswered Questions and the Role of ctDNA Dynamics in Selecting Intensification Candidates in EGFR-Mutant NSCLC
5






































































